Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. BioDefense Seeks To Manufacture Roche’s Tamiflu

This article was originally published in The Pink Sheet Daily

Executive Summary

Department of Defense contractor says details of how Roche will sublicense manufacturing responsibilities for the antiviral remain undecided.

You may also be interested in...



Ranbaxy Estimates Production Capacity For Generic Tamiflu

The generics firm said it will be capable of producing the Roche antiviral’s active pharmaceutical ingredient at a rate of 22 tons per annum.

Ranbaxy Estimates Production Capacity For Generic Tamiflu

The generics firm said it will be capable of producing the Roche antiviral’s active pharmaceutical ingredient at a rate of 22 tons per annum.

Roche To Meet With Generic Firms On Tamiflu Rights After Intervention From Senators

Roche agrees to meet with Teva, Mylan, Ranbaxy and Barr to discuss granting manufacturing rights for Tamiflu in order to meet growing global demand for the avian flu antiviral.

Related Content

Topics

UsernamePublicRestriction

Register

PS061324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel